Palvella Therapeutics begins Phase 2 trial for rare skin condition

May 4, 2026 7:30 AM

Palvella Therapeutics Inc. (NASDAQ: PVLA) announced that the first patients have been dosed in its Phase 2 LOTU clinical trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found